Last reviewed · How we verify
J65 vaccine then E39 vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
J65 vaccine then E39 vaccine (J65 vaccine then E39 vaccine) — COL George Peoples, MD, FACS.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| J65 vaccine then E39 vaccine TARGET | J65 vaccine then E39 vaccine | COL George Peoples, MD, FACS | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- J65 vaccine then E39 vaccine CI watch — RSS
- J65 vaccine then E39 vaccine CI watch — Atom
- J65 vaccine then E39 vaccine CI watch — JSON
- J65 vaccine then E39 vaccine alone — RSS
Cite this brief
Drug Landscape (2026). J65 vaccine then E39 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/j65-vaccine-then-e39-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab